{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T16:13:38Z","timestamp":1787242418592,"version":"build-2736575974"},"reference-count":109,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,1,24]],"date-time":"2019-01-24T00:00:00Z","timestamp":1548288000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ebiomedicine.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["EBioMedicine"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1016\/j.ebiom.2019.01.050","type":"journal-article","created":{"date-parts":[[2019,2,4]],"date-time":"2019-02-04T19:09:09Z","timestamp":1549307349000},"page":"363-374","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":97,"special_numbering":"C","title":["Biomarker concordance between primary colorectal cancer and its metastases"],"prefix":"10.1016","volume":"40","author":[{"given":"D.S.","family":"Bhullar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Barriuso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Mullamitha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.P.","family":"Saunders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.T.","family":"O'Dwyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Aziz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ebiom.2019.01.050_bb0005","series-title":"SEER Cancer Statistics Review, 1975\u20132015","author":"Noone","year":"2018"},{"issue":"Suppl_3","key":"10.1016\/j.ebiom.2019.01.050_bb0010","doi-asserted-by":"crossref","first-page":"iii1","DOI":"10.1093\/annonc\/mdu260","article-title":"Metastatic colorectal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up\u2020","volume":"25","author":"Van Cutsem","year":"2014","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.ebiom.2019.01.050_bb0015","doi-asserted-by":"crossref","first-page":"E359","DOI":"10.1002\/ijc.29210","article-title":"Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012","volume":"136","author":"Ferlay","year":"2015","journal-title":"Int J Cancer"},{"issue":"42","key":"10.1016\/j.ebiom.2019.01.050_bb0020","doi-asserted-by":"crossref","first-page":"5375","DOI":"10.3748\/wjg.v16.i42.5375","article-title":"Patterns of lymph node metastasis are different in colon and rectal carcinomas","volume":"16","author":"Wang","year":"2010","journal-title":"World J Gastroenterol"},{"issue":"4","key":"10.1016\/j.ebiom.2019.01.050_bb0025","first-page":"496","article-title":"The clinical correlation of an autopsy study of recurrent colorectal cancer","volume":"189","author":"Welch","year":"1979","journal-title":"Ann Surg"},{"issue":"2","key":"10.1016\/j.ebiom.2019.01.050_bb0030","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1046\/j.1365-2168.1999.01013.x","article-title":"Treatment of colorectal liver metastases","volume":"86","author":"Geoghegan","year":"1999","journal-title":"BJS"},{"issue":"1","key":"10.1016\/j.ebiom.2019.01.050_bb0035","first-page":"27","article-title":"Patterns of recurrence after curative resection of carcinoma of the colon and rectum","volume":"174","author":"Galandiuk","year":"1992","journal-title":"Surg Gynecol Obstet"},{"issue":"5","key":"10.1016\/j.ebiom.2019.01.050_bb0040","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1002\/bjs.8679","article-title":"Incidence, prevalence and risk factors for peritoneal carcinomatosis from colorectal cancer","volume":"99","author":"Segelman","year":"2012","journal-title":"Br J Surg"},{"issue":"2","key":"10.1016\/j.ebiom.2019.01.050_bb0045","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1097\/01.sla.0000197702.46394.16","article-title":"Peritoneal carcinomatosis of colorectal origin: incidence and current treatment strategies","volume":"243","author":"Koppe","year":"2006","journal-title":"Ann Surg"},{"key":"10.1016\/j.ebiom.2019.01.050_bb0050","doi-asserted-by":"crossref","first-page":"29765","DOI":"10.1038\/srep29765","article-title":"Patterns of metastasis in colon and rectal cancer","volume":"6","author":"Riihim\u00e4ki","year":"2016","journal-title":"Sci Rep"},{"issue":"5","key":"10.1016\/j.ebiom.2019.01.050_bb0055","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.3748\/wjg.v22.i5.1745","article-title":"Colorectal cancer tumour markers and biomarkers: recent therapeutic advances","volume":"22","author":"Lech","year":"2016","journal-title":"World J Gastroenterol"},{"issue":"7407","key":"10.1016\/j.ebiom.2019.01.050_bb0060","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/nature11252","article-title":"Comprehensive molecular characterization of human colon and rectal cancer","volume":"487","author":"Network","year":"2012","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.ebiom.2019.01.050_bb0065","doi-asserted-by":"crossref","first-page":"3992","DOI":"10.1158\/0008-5472.CAN-06-0191","article-title":"KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer","volume":"66","author":"Lievre","year":"2006","journal-title":"Cancer Res"},{"issue":"4","key":"10.1016\/j.ebiom.2019.01.050_bb0070","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/sj.bjc.6605177","article-title":"KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer","volume":"101","author":"Loupakis","year":"2009","journal-title":"Br J Cancer"},{"issue":"9","key":"10.1016\/j.ebiom.2019.01.050_bb0075","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1634\/theoncologist.2013-0107","article-title":"Efficacy and safety of bevacizumab in metastatic colorectal cancer: pooled analysis from seven randomized controlled trials","volume":"18","author":"Hurwitz","year":"2013","journal-title":"Oncologist"},{"issue":"1\u20132","key":"10.1016\/j.ebiom.2019.01.050_bb0080","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1159\/000452551","article-title":"Efficacy of bevacizumab in the first-line treatment of patients with RAS mutations metastatic colorectal cancer: a systematic review and network meta-analysis","volume":"40","author":"Zhou","year":"2016","journal-title":"Cell Physiol Biochem"},{"issue":"1","key":"10.1016\/j.ebiom.2019.01.050_bb0085","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1093\/annonc\/mdu378","article-title":"Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials","volume":"26","author":"Sorich","year":"2014","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"issue":"24","key":"10.1016\/j.ebiom.2019.01.050_bb0090","doi-asserted-by":"crossref","first-page":"5469","DOI":"10.1158\/1078-0432.CCR-15-0526","article-title":"Analysis of KRAS\/NRAS Mutations in a phase III study of panitumumab with FOLFIRI compared with FOLFIRI alone as second-line treatment for metastatic colorectal cancer","volume":"21","author":"Peeters","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"6892","key":"10.1016\/j.ebiom.2019.01.050_bb0095","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/nature00766","article-title":"Mutations of the BRAF gene in human cancer","volume":"417","author":"Davies","year":"2002","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.ebiom.2019.01.050_bb0100","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1002\/gcc.20854","article-title":"Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer","volume":"50","author":"Vaughn","year":"2011","journal-title":"Genes Chromosomes Cancer"},{"issue":"9783","key":"10.1016\/j.ebiom.2019.01.050_bb0105","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1016\/S0140-6736(11)60613-2","article-title":"Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial","volume":"377","author":"Maughan","year":"2011","journal-title":"Lancet (London, England)"},{"issue":"6","key":"10.1016\/j.ebiom.2019.01.050_bb0110","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/S1470-2045(10)70209-6","article-title":"KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer","volume":"12","author":"De Roock","year":"2011","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.ebiom.2019.01.050_bb0115","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1093\/annonc\/mdr464","article-title":"PIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis","volume":"23","author":"Mao","year":"2012","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"issue":"16","key":"10.1016\/j.ebiom.2019.01.050_bb0120","doi-asserted-by":"crossref","first-page":"2622","DOI":"10.1200\/JCO.2008.20.2796","article-title":"PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer","volume":"27","author":"Loupakis","year":"2009","journal-title":"J Clin Oncol"},{"issue":"35","key":"10.1016\/j.ebiom.2019.01.050_bb0125","doi-asserted-by":"crossref","first-page":"5924","DOI":"10.1200\/JCO.2008.21.6796","article-title":"Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer","volume":"27","author":"Laurent-Puig","year":"2009","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.ebiom.2019.01.050_bb0130","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/S0959-8049(02)00040-0","article-title":"The APC gene in colorectal cancer","volume":"38","author":"Fodde","year":"2002","journal-title":"Eur J Cancer"},{"issue":"6","key":"10.1016\/j.ebiom.2019.01.050_bb0135","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1093\/carcin\/bgm012","article-title":"Mutations in TP53 are a prognostic factor in colorectal hepatic metastases undergoing surgical resection","volume":"28","author":"Mollev\u00ed","year":"2007","journal-title":"Carcinogenesis"},{"issue":"1","key":"10.1016\/j.ebiom.2019.01.050_bb0140","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1186\/1471-2407-13-277","article-title":"Integral analysis of p53 and its value as prognostic factor in sporadic colon cancer","volume":"13","author":"Fari\u00f1a Sarasqueta","year":"2013","journal-title":"BMC Cancer"},{"issue":"24","key":"10.1016\/j.ebiom.2019.01.050_bb0145","doi-asserted-by":"crossref","first-page":"5635","DOI":"10.1200\/JCO.2005.04.096","article-title":"Determination of TP53 mutation is more relevant than microsatellite instability status for the prediction of disease-free survival in adjuvant-treated stage III colon cancer patients","volume":"23","author":"Westra","year":"2005","journal-title":"J Clin Oncol"},{"issue":"30","key":"10.1016\/j.ebiom.2019.01.050_bb0150","doi-asserted-by":"crossref","first-page":"7518","DOI":"10.1200\/JCO.2005.00.471","article-title":"The TP53 colorectal cancer international collaborative study on the prognostic and predictive significance of p53 mutation: influence of tumor site, type of mutation, and adjuvant treatment","volume":"23","author":"Russo","year":"2005","journal-title":"J Clin Oncol"},{"issue":"20","key":"10.1016\/j.ebiom.2019.01.050_bb0155","doi-asserted-by":"crossref","first-page":"3098","DOI":"10.1038\/sj.onc.1202642","article-title":"Higher frequency of Smad4 gene mutation in human colorectal cancer with distant metastasis","volume":"18","author":"Miyaki","year":"1999","journal-title":"Oncogene"},{"issue":"7","key":"10.1016\/j.ebiom.2019.01.050_bb0160","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1158\/1078-0432.CCR-04-1458","article-title":"SMAD4 as a prognostic marker in colorectal cancer","volume":"11","author":"Alazzouzi","year":"2005","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.ebiom.2019.01.050_bb0165","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1136\/jclinpath-2014-202660","article-title":"Smad4 inactivation predicts for worse prognosis and response to fluorouracil-based treatment in colorectal cancer","volume":"68","author":"Kozak","year":"2015","journal-title":"J Clin Pathol"},{"issue":"7","key":"10.1016\/j.ebiom.2019.01.050_bb0170","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1038\/nm.3870","article-title":"Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients","volume":"21","author":"Siravegna","year":"2015","journal-title":"Nat Med"},{"issue":"9","key":"10.1016\/j.ebiom.2019.01.050_bb0175","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1634\/theoncologist.2011-0024","article-title":"Concordance of predictive markers for EGFR inhibitors in primary tumors and metastases in colorectal cancer: a review","volume":"16","author":"Baas","year":"2011","journal-title":"Oncologist"},{"key":"10.1016\/j.ebiom.2019.01.050_bb0180","doi-asserted-by":"crossref","first-page":"8065","DOI":"10.1038\/srep08065","article-title":"Concordant analysis of KRAS, BRAF, PIK3CA mutations, and PTEN expression between primary colorectal cancer and matched metastases","volume":"5","author":"Mao","year":"2015","journal-title":"Sci Rep"},{"issue":"10","key":"10.1016\/j.ebiom.2019.01.050_bb0185","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1113205","article-title":"Intratumor heterogeneity and branched evolution revealed by multiregion sequencing","volume":"366","author":"Gerlinger","year":"2012","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.ebiom.2019.01.050_bb0190","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"issue":"4","key":"10.1016\/j.ebiom.2019.01.050_bb0195","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1214\/aoms\/1177729756","article-title":"Transformations related to the angular and the square root","volume":"21","author":"Freeman","year":"1950","journal-title":"Ann Math Stat"},{"issue":"4","key":"10.1016\/j.ebiom.2019.01.050_bb0200","first-page":"138","article-title":"The inverse of the freeman \u2013 Tukey double arcsine transformation","volume":"32","author":"Miller","year":"1978","journal-title":"Am Stat"},{"issue":"3","key":"10.1016\/j.ebiom.2019.01.050_bb0205","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"issue":"7414","key":"10.1016\/j.ebiom.2019.01.050_bb0210","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"issue":"7109","key":"10.1016\/j.ebiom.2019.01.050_bb0215","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"issue":"39","key":"10.1016\/j.ebiom.2019.01.050_bb0220","doi-asserted-by":"crossref","first-page":"64999","DOI":"10.18632\/oncotarget.17048","article-title":"Molecular profiling of colorectal pulmonary metastases and primary tumours: implications for targeted treatment","volume":"8","author":"Moorcraft","year":"2017","journal-title":"Oncotarget"},{"issue":"2","key":"10.1016\/j.ebiom.2019.01.050_bb0225","doi-asserted-by":"crossref","first-page":"785","DOI":"10.3892\/or.2016.5323","article-title":"High concordance rate of KRAS\/BRAF mutations and MSI-H between primary colorectal cancer and corresponding metastases","volume":"37","author":"Fujiyoshi","year":"2017","journal-title":"Oncol Rep"},{"issue":"9","key":"10.1016\/j.ebiom.2019.01.050_bb0230","first-page":"1978","article-title":"KRAS mutation status is highly homogeneous between areas of the primary tumor and the corresponding metastasis of colorectal adenocarcinomas: one less problem in patient care","volume":"7","author":"Petaccia de Macedo","year":"2017","journal-title":"Am J Cancer Res"},{"key":"10.1016\/j.ebiom.2019.01.050_bb0235","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.2147\/OTT.S133203","article-title":"Association between clinicopathological features and survival in patients with primary and paired metastatic colorectal cancer and KRAS mutation","volume":"10","author":"Pang","year":"2017","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.ebiom.2019.01.050_bb0240","doi-asserted-by":"crossref","first-page":"4695","DOI":"10.2147\/OTT.S102891","article-title":"Mutational analysis of primary and metastatic colorectal cancer samples underlying the resistance to cetuximab-based therapy","volume":"9","author":"Nemecek","year":"2016","journal-title":"Onco Targets Ther"},{"issue":"7","key":"10.1016\/j.ebiom.2019.01.050_bb0245","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s12032-016-0787-z","article-title":"Comparison of KRAS mutation status between primary tumor and metastasis in Chinese colorectal cancer patients","volume":"33","author":"Li","year":"2016","journal-title":"Med Oncol"},{"key":"10.1016\/j.ebiom.2019.01.050_bb0250","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.2147\/OTT.S97668","article-title":"Comparison of KRAS and PIK3CA gene status between primary tumors and paired metastases in colorectal cancer","volume":"9","author":"He","year":"2016","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.ebiom.2019.01.050_bb0255","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s12943-016-0549-8","article-title":"Spatio-temporal mutation profiles of case-matched colorectal carcinomas and their metastases reveal unique de novo mutations in metachronous lung metastases by targeted next generation sequencing","volume":"15","author":"Kovaleva","year":"2016","journal-title":"Mol Cancer"},{"issue":"6","key":"10.1016\/j.ebiom.2019.01.050_bb0260","doi-asserted-by":"crossref","first-page":"529","DOI":"10.5858\/arpa.2015-0261-SA","article-title":"Next-generation sequencing of matched primary and metastatic rectal adenocarcinomas demonstrates minimal mutation gain and concordance to colonic adenocarcinomas","volume":"140","author":"Crumley","year":"2016","journal-title":"Arch Pathol Lab Med"},{"issue":"7","key":"10.1016\/j.ebiom.2019.01.050_bb0265","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.ejca.2015.02.012","article-title":"Comparative analysis of primary tumour and matched metastases in colorectal cancer patients: evaluation of concordance between genomic and transcriptional profiles","volume":"51","author":"Vignot","year":"2015","journal-title":"Eur J Cancer"},{"issue":"8","key":"10.1016\/j.ebiom.2019.01.050_bb0270","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1097\/PAS.0000000000000423","article-title":"Distinctive spatiotemporal stability of somatic mutations in metastasized microsatellite-stable colorectal cancer","volume":"39","author":"Jesinghaus","year":"2015","journal-title":"Am J Surg Pathol"},{"issue":"1","key":"10.1016\/j.ebiom.2019.01.050_bb0275","first-page":"128","article-title":"KRAS discordance between primary and metastatic tumor in patients with metastatic colorectal carcinoma","volume":"20","author":"Siyar Ekinci","year":"2015","journal-title":"J BUON"},{"key":"10.1016\/j.ebiom.2019.01.050_bb0280","series-title":"Discordant RAS Status Between Primary and Metastatic Colorectal Cancer and Predicted Pattern of Metastases","volume":"26","author":"Lau","year":"2015"},{"issue":"8","key":"10.1016\/j.ebiom.2019.01.050_bb0285","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1002\/jso.23936","article-title":"KRAS discordance between primary and recurrent tumors after radical resection of colorectal cancers","volume":"111","author":"Lee","year":"2015","journal-title":"J Surg Oncol"},{"issue":"26","key":"10.1016\/j.ebiom.2019.01.050_bb0290","doi-asserted-by":"crossref","first-page":"22179","DOI":"10.18632\/oncotarget.4246","article-title":"Genome-wide mutation profiles of colorectal tumors and associated liver metastases at the exome and transcriptome levels","volume":"6","author":"Lim","year":"2015","journal-title":"Oncotarget"},{"issue":"5","key":"10.1016\/j.ebiom.2019.01.050_bb0295","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0126670","article-title":"co-evolution of somatic variation in primary and metastatic colorectal cancer may expand biopsy indications in the molecular era","volume":"10","author":"Kim","year":"2015","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.ebiom.2019.01.050_bb0300","first-page":"5927","article-title":"Comparison of neuroendocrine differentiation and KRAS\/NRAS\/BRAF\/PIK3CA\/TP53 mutation status in primary and metastatic colorectal cancer","volume":"7","author":"Kleist","year":"2014","journal-title":"Int J Clin Exp Pathol"},{"issue":"5","key":"10.1016\/j.ebiom.2019.01.050_bb0305","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.3892\/ol.2014.1905","article-title":"KRAS and BRAF genotyping of synchronous colorectal carcinomas","volume":"7","author":"Giannini","year":"2014","journal-title":"Oncol Lett"},{"issue":"4","key":"10.1016\/j.ebiom.2019.01.050_bb0310","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.3892\/ol.2014.2411","article-title":"KRAS mutational concordance between primary and metastatic colorectal adenocarcinoma","volume":"8","author":"PALIOGIANNIS","year":"2014","journal-title":"Oncol Lett"},{"issue":"8","key":"10.1016\/j.ebiom.2019.01.050_bb0315","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1186\/s13059-014-0454-7","article-title":"Comparative sequencing analysis reveals high genomic concordance between matched primary and metastatic colorectal cancer lesions","volume":"15","author":"Brannon","year":"2014","journal-title":"Genome Biol"},{"issue":"3","key":"10.1016\/j.ebiom.2019.01.050_bb0320","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0090459","article-title":"Comparative genomic analysis of primary and synchronous metastatic colorectal cancers","volume":"9","author":"Lee","year":"2014","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.ebiom.2019.01.050_bb0325","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1038\/bjc.2013.289","article-title":"Methylation levels of LINE-1 in primary lesion and matched metastatic lesions of colorectal cancer","volume":"109","author":"Murata","year":"2013","journal-title":"Br J Cancer"},{"issue":"4","key":"10.1016\/j.ebiom.2019.01.050_bb0330","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.prp.2013.02.006","article-title":"Mutation analysis of KRAS in primary colorectal cancer and matched metastases by means of highly sensitivity molecular assay","volume":"209","author":"Miglio","year":"2013","journal-title":"Pathol Res Pract"},{"key":"10.1016\/j.ebiom.2019.01.050_bb0335","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1038\/modpathol.2012.150","article-title":"Combined analysis of KRAS and PIK3CA mutations, MET and PTEN expression in primary tumors and corresponding metastases in colorectal cancer","volume":"26","author":"Voutsina","year":"2013","journal-title":"Mod Pathol"},{"issue":"24","key":"10.1016\/j.ebiom.2019.01.050_bb0340","doi-asserted-by":"crossref","first-page":"2956","DOI":"10.1200\/JCO.2011.38.2994","article-title":"Comparative genomic analysis of primary versus metastatic colorectal carcinomas","volume":"30","author":"Vakiani","year":"2012","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ebiom.2019.01.050_bb0345","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1158\/1078-0432.CCR-11-1965","article-title":"Primary colorectal cancers and their subsequent hepatic metastases are genetically different: implications for selection of patients for targeted treatment","volume":"18","author":"Vermaat","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.ebiom.2019.01.050_bb0350","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1038\/bjc.2011.26","article-title":"KRAS mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients","volume":"104","author":"Knijn","year":"2011","journal-title":"Br J Cancer"},{"issue":"4","key":"10.1016\/j.ebiom.2019.01.050_bb0355","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1007\/s00280-011-1586-z","article-title":"Analysis of KRAS, BRAF, PTEN, IGF1R, EGFR intron 1 CA status in both primary tumors and paired metastases in determining benefit from cetuximab therapy in colon cancer","volume":"68","author":"Park","year":"2011","journal-title":"Cancer Chemother Pharmacol"},{"issue":"9","key":"10.1016\/j.ebiom.2019.01.050_bb0360","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1097\/DCR.0b013e31821d37a3","article-title":"Heterogeneity of KRAS status may explain the subset of discordant KRAS status between primary and metastatic colorectal cancer","volume":"54","author":"Watanabe","year":"2011","journal-title":"Dis Colon Rectum"},{"issue":"3","key":"10.1016\/j.ebiom.2019.01.050_bb0365","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1158\/1078-0432.CCR-09-2446","article-title":"Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases","volume":"16","author":"Baldus","year":"2010","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.ebiom.2019.01.050_bb0370","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1245\/s10434-009-0864-z","article-title":"KRAS and BRAF mutational status in primary colorectal tumors and related metastatic sites: biological and clinical implications","volume":"17","author":"Italiano","year":"2010","journal-title":"Ann Surg Oncol"},{"issue":"10","key":"10.1016\/j.ebiom.2019.01.050_bb0375","first-page":"4229","article-title":"Concordant analysis of KRAS status in primary colon carcinoma and matched metastasis","volume":"30","author":"Mariani","year":"2010","journal-title":"Anticancer Res"},{"issue":"1","key":"10.1016\/j.ebiom.2019.01.050_bb0380","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1093\/annonc\/mdn541","article-title":"PI3KCA\/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients","volume":"20","author":"Perrone","year":"2009","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"issue":"12","key":"10.1016\/j.ebiom.2019.01.050_bb0385","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0008199","article-title":"KRAS mutations in primary colorectal cancer tumors and related metastases: a potential role in prediction of lung metastasis","volume":"4","author":"Cejas","year":"2009","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.ebiom.2019.01.050_bb0390","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1093\/annonc\/mdn712","article-title":"The importance of KRAS mutations and EGF61A>G polymorphism to the effect of cetuximab and irinotecan in metastatic colorectal cancer","volume":"20","author":"Garm Spindler","year":"2009","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"issue":"7","key":"10.1016\/j.ebiom.2019.01.050_bb0395","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1038\/sj.bjc.6604848","article-title":"Differing deregulation of EGFR and downstream proteins in primary colorectal cancer and related metastatic sites may be clinically relevant","volume":"100","author":"Molinari","year":"2009","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ebiom.2019.01.050_bb0400","doi-asserted-by":"crossref","first-page":"831626","DOI":"10.1155\/2009\/831626","article-title":"Concordance of KRAS\/BRAF mutation status in metastatic colorectal cancer before and after anti-EGFR therapy","volume":"2009","author":"Gattenl\u00f6hner","year":"2009","journal-title":"J Oncol"},{"issue":"15","key":"10.1016\/j.ebiom.2019.01.050_bb0405","doi-asserted-by":"crossref","first-page":"4830","DOI":"10.1158\/1078-0432.CCR-07-4906","article-title":"K-Ras mutations and treatment outcome in colorectal cancer patients receiving exclusive fluoropyrimidine therapy","volume":"14","author":"Etienne-Grimaldi","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"12","key":"10.1016\/j.ebiom.2019.01.050_bb0410","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1634\/theoncologist.2008-0181","article-title":"High concordance of KRAS status between primary colorectal tumors and related metastatic sites: implications for clinical practice","volume":"13","author":"Santini","year":"2008","journal-title":"Oncologist"},{"key":"10.1016\/j.ebiom.2019.01.050_bb0415","doi-asserted-by":"crossref","first-page":"4217","DOI":"10.1200\/JCO.2008.18.7286","article-title":"Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer","volume":"26","author":"Artale","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ebiom.2019.01.050_bb0420","first-page":"835","article-title":"K-ras mutations and cetuximab in colorectal cancer","volume":"360","author":"Gattenlohner","year":"2008","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.ebiom.2019.01.050_bb0425","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1002\/ijc.22343","article-title":"Allelotyping analyses of synchronous primary and metastasis CIN colon cancers identified different subtypes","volume":"120","author":"Weber","year":"2007","journal-title":"Int J Cancer"},{"issue":"1","key":"10.1016\/j.ebiom.2019.01.050_bb0430","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/sj.onc.1209758","article-title":"KRAS and BRAF oncogenic mutations in MSS colorectal carcinoma progression","volume":"26","author":"Oliveira","year":"2007","journal-title":"Oncogene"},{"issue":"3","key":"10.1016\/j.ebiom.2019.01.050_bb0435","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.bbrc.2004.10.111","article-title":"Heterogeneity within and between primary colorectal carcinomas and matched metastases as revealed by analysis of Ki-ras and p53 mutations","volume":"325","author":"Albanese","year":"2004","journal-title":"Biochem Biophys Res Commun"},{"issue":"3","key":"10.1016\/j.ebiom.2019.01.050_bb0440","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1136\/mp.56.3.137","article-title":"Molecular changes in the Ki-ras and APC genes in primary colorectal carcinoma and synchronous metastases compared with the findings in accompanying adenomas","volume":"56","author":"Zauber","year":"2003","journal-title":"Mol Pathol"},{"issue":"11","key":"10.1016\/j.ebiom.2019.01.050_bb0445","doi-asserted-by":"crossref","first-page":"2837","DOI":"10.1200\/JCO.2001.19.11.2837","article-title":"Discordance between K-ras mutations in bone marrow micrometastases and the primary tumor in colorectal cancer","volume":"19","author":"Tortola","year":"2001","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ebiom.2019.01.050_bb0450","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1002\/(SICI)1096-9896(199806)185:2<130::AID-PATH85>3.0.CO;2-M","article-title":"Heterogeneity of mutant versus wild-type Ki-ras in primary and metastatic colorectal carcinomas, and association of codon-12 valine with early mortality","volume":"185","author":"Al-Mulla","year":"1998","journal-title":"J Pathol"},{"issue":"1","key":"10.1016\/j.ebiom.2019.01.050_bb0455","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1002\/ijc.2910520107","article-title":"K-ras point mutations in human colorectal carcinomas: relation to aneuploidy and metastasis","volume":"52","author":"Suchy","year":"1992","journal-title":"Int J Cancer"},{"issue":"6\u20137","key":"10.1016\/j.ebiom.2019.01.050_bb0460","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/0959-8049(92)90468-H","article-title":"Stability of K-ras mutations throughout the natural history of human colorectal cancer","volume":"28A","author":"Losi","year":"1992","journal-title":"Eur J Cancer"},{"issue":"6","key":"10.1016\/j.ebiom.2019.01.050_bb0465","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1002\/ijc.2910490613","article-title":"Differential activation of ras genes by point mutation in human colon cancer with metastases to either lung or liver","volume":"49","author":"Oudejans","year":"1991","journal-title":"Int J Cancer"},{"issue":"4","key":"10.1016\/j.ebiom.2019.01.050_bb0470","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1002\/cam4.97","article-title":"PTEN expression is consistent in colorectal cancer primaries and metastases and associates with patient survival","volume":"2","author":"Atreya","year":"2013","journal-title":"Cancer Med"},{"issue":"5","key":"10.1016\/j.ebiom.2019.01.050_bb0475","doi-asserted-by":"crossref","first-page":"416","DOI":"10.4161\/cbt.10.5.12610","article-title":"EGFR expression variance in paired colorectal cancer primary and metastatic tumors","volume":"10","author":"Yarom","year":"2010","journal-title":"Cancer Biol Ther"},{"issue":"23","key":"10.1016\/j.ebiom.2019.01.050_bb0480","doi-asserted-by":"crossref","first-page":"4772","DOI":"10.1200\/JCO.2004.00.117","article-title":"Epidermal growth factor receptor (EGFR) status in primary colorectal tumors does not correlate with EGFR expression in related metastatic sites: implications for treatment with EGFR-targeted monoclonal antibodies","volume":"22","author":"Scartozzi","year":"2004","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ebiom.2019.01.050_bb0485","doi-asserted-by":"crossref","first-page":"129","DOI":"10.4132\/jptm.2016.12.09","article-title":"Comparison of the mismatch repair system between primary and metastatic colorectal cancers using immunohistochemistry","volume":"51","author":"Jung","year":"2017","journal-title":"J Pathol Transl Med"},{"issue":"2","key":"10.1016\/j.ebiom.2019.01.050_bb0490","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s10689-015-9856-2","article-title":"Mismatch repair deficiency concordance between primary colorectal cancer and corresponding metastasis","volume":"15","author":"Haraldsdottir","year":"2016","journal-title":"Familial Cancer"},{"key":"10.1016\/j.ebiom.2019.01.050_bb0495","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s13148-017-0347-1","article-title":"The CpG island methylator phenotype is concordant between primary colorectal carcinoma and matched distant metastases","volume":"9","author":"Cohen","year":"2017","journal-title":"Clin Epigenetics"},{"issue":"3","key":"10.1016\/j.ebiom.2019.01.050_bb0500","doi-asserted-by":"crossref","DOI":"10.1177\/1010428317692246","article-title":"Mitochondrial DNA alteration in primary and metastatic colorectal cancer: different frequency and association with selected clinicopathological and molecular markers","volume":"39","author":"Kleist","year":"2017","journal-title":"Tumour Biol"},{"issue":"10","key":"10.1016\/j.ebiom.2019.01.050_bb0505","article-title":"MiR expression profiles of paired primary colorectal cancer and metastases by next-generation sequencing","volume":"4","author":"Neerincx","year":"2015","journal-title":"Oncogene"},{"issue":"4","key":"10.1016\/j.ebiom.2019.01.050_bb0510","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.jmoldx.2011.03.002","article-title":"KRAS, NRAS, PIK3CA Exon 20, and BRAF genotypes in synchronous and metachronous primary colorectal cancers: diagnostic and therapeutic implications","volume":"13","author":"Balschun","year":"2011","journal-title":"J Mol Diagn"},{"issue":"1","key":"10.1016\/j.ebiom.2019.01.050_bb0515","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.ejso.2017.10.211","article-title":"Exome sequencing of synchronously resected primary colorectal tumours and colorectal liver metastases to inform oncosurgical management","volume":"44","author":"Sutton","year":"2018","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.ebiom.2019.01.050_bb0520","doi-asserted-by":"crossref","DOI":"10.1186\/s13059-015-0589-1","article-title":"High-depth sequencing of over 750 genes supports linear progression of primary tumors and metastases in most patients with liver-limited metastatic colorectal cancer","volume":"16","author":"Tan","year":"2015","journal-title":"Genome Biol"},{"key":"10.1016\/j.ebiom.2019.01.050_bb0525","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/nrc3261","article-title":"Intra-tumour heterogeneity: a looking glass for cancer?","volume":"12","author":"Marusyk","year":"2012","journal-title":"Nat Rev Cancer"},{"issue":"5","key":"10.1016\/j.ebiom.2019.01.050_bb0530","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1093\/carcin\/bgi044","article-title":"Evolution of intratumoral genetic heterogeneity during colorectal cancer progression","volume":"26","author":"Losi","year":"2005","journal-title":"Carcinogenesis"},{"issue":"12","key":"10.1016\/j.ebiom.2019.01.050_bb0535","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1016\/S1470-2045(16)30500-9","article-title":"Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database","volume":"17","author":"Franko","year":"2016","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.ebiom.2019.01.050_bb0540","doi-asserted-by":"crossref","first-page":"2644","DOI":"10.1158\/1078-0432.CCR-14-2391","article-title":"Hotspot mutation panel testing reveals clonal evolution in a study of 265 paired primary and metastatic tumors","volume":"21","author":"Goswami","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.ebiom.2019.01.050_bb0545","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1177\/1758834015614530","article-title":"Pharmacologic resistance in colorectal cancer: a review","volume":"8","author":"Hammond","year":"2016","journal-title":"Ther Adv Med Oncol"}],"container-title":["EBioMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S235239641930057X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S235239641930057X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,7,8]],"date-time":"2019-07-08T11:48:25Z","timestamp":1562586505000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S235239641930057X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":109,"alternative-id":["S235239641930057X"],"URL":"https:\/\/doi.org\/10.1016\/j.ebiom.2019.01.050","relation":{},"ISSN":["2352-3964"],"issn-type":[{"value":"2352-3964","type":"print"}],"subject":[],"published":{"date-parts":[[2019,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biomarker concordance between primary colorectal cancer and its metastases","name":"articletitle","label":"Article Title"},{"value":"EBioMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ebiom.2019.01.050","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}